Sentences with phrase «vaccine platforms for»

He is particularly interested in genetic and host determinants of virus replication and how this knowledge can be applied towards the development of self - replicating RNA vaccine platforms for emerging infectious diseases.

Trevor Mundel, president of global health at the Gates Foundation, talks to Scientific American editor - in - chief Mariette DiChristina about the Coalition for Epidemic Preparedness Innovations (CEPI) and the efforts to create vaccine platforms for rapid responses to epidemics.

Not exact matches

«We are honored to receive this award which underscores the unique value of our technology platform and its game changing potential to make novel vaccines for important human diseases.»

«In addition, this platform can be used to develop safe vaccine candidates for other flaviviruses such as Zika virus, where pregnant women are the target group for vaccination.»

Beyond its $ 100 - millionper - year platform research, Moderna runs four wholly owned ventures focused on drugs for infectious diseases, rare diseases, immuno - oncology, and personalized cancer vaccines.

The findings underscore the need for targeted research to further evaluate manufacturing strategies and vaccine antigens and platforms, according to the authors.

Being a startup valued at more than a billion dollars — an anomaly that venture capitalists dub a unicorn — comes with scrutiny, and many wonder whether Moderna's pipeline, consisting mostly of vaccines for now, will expand to match the company's original vision of mRNA as a broad treatment platform.

Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.

Scientists are also breaking ground with nucleic acid platforms that have the potential to deliver cancer vaccines, for neoantigens and other targets.

IDMIT will contribute 1) To the development and validation of assays based on flow cytometry and mass cytometry for the evaluation of immune responses in humans and animal models; these tools will be particularly relevant for the identification of signatures of vaccine efficacy; 2) To the animal model platform, in particularly by providing access to NHP models and to new technologies for in vivo imaging infections and host responses; 3) To networking activities, in particular by organising a workshop on in vivo imaging.

«The Army was able to move so quickly in developing, manufacturing and testing a Zika vaccine because of its extensive experience with this vaccine platform and long standing investments in the understanding and mitigation of flaviviruses, like yellow fever, dating back to the founding of WRAIR,» said Dr. Kayvon Modjarrad, Zika program co-lead and associate director for Emerging Infectious Disease Threats at WRAIR's MHRP.

Extending cytokine / chemokine profiling platform (UNISI): Improvement of currently available services will be particularly focused on the optimisation of cytokine profiling for vaccine relevance using a systems biology approach.

The Fraunhofer IME leads the Transnational Access 1 (TNA1) «Cross platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «both aiming at the provision of comprehensive range of different well established pro- and eukaryotic expression / production systems to identify the optimal manufacturing platform for any given vaccine candidate.

This platform aims to provide users with access to adjuvants (suitable for pre-clinical use), access to customised vaccine formulation studies, and access to stability studies for adjuvanted vaccines.

The Transnational Access 1 (TNA1) «Cross platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «will combine the expertise of six different partners (IME, SSI, UOXF, iBET, BPRC and UNISI) to provide the unique offer to test vaccine candidates in a comprehensive range of different expression hosts, to identify the optimal production system for further pre-clinical and clinical development.

TRANSVAC workshop on standardisation and harmonisation of analysis platforms for HIV, TB and malaria vaccines.

The integrated production platform aims to produce and purify these proteins using a combination of engineered microbial cell factories and flexible approaches for purification to accommodate different vaccines and future candidates.

The overall objective of PlacID is to validate the non-human primate animal model developed at NIAID - LMIV for the evaluation of the placental malaria vaccine candidates and to assess it as a platform for testing placental malaria vaccine candidates prior to human testing.

In a second study, the goal is to assess the Aotus model of P. falciparum placental malaria as a platform for assessing placental malaria vaccine candidates.

Prior to joining IDRI, Neal worked as a research scientist for Immune Design Corporation (IDC), where he was a member of a team focused on design, generation, and testing of a novel viral vector vaccine platform.

Research on vaccine biomarkers, including in - depth comparative analysis of data from different platforms, large - scale RNA sequencing, harmonisation of standard operating procedures (SOPs) for sample, microarray and data analysis, as well as transcriptome mapping (more than 1400 samples analysed).

TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: «How can big data help?»

Recent research focuses on vaccine development in accordance with current ICH guidelines (QbD and PAT) and the development of new platform - technology for vaccines.

The Wistar Institute was awarded a $ 1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA - based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Revaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer ReVaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.

«Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development» (DOI: 10.3389 / fpls.2015.01169)

PHILADELPHIA - Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.

Preparation and global prosecution of patent applications directed to diagnostic and therapeutic products including antibodies, gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.

DHHS BARDA Contract, 2006, 15,000,000 PI - Transcutaneous Immunization for Tetanus Booster, 1998, NIAID Phase 1 SBIR, $ 100,000 PI - Transcutaneous Immunization for DNA, 1998, NIAID Phase 1 SBIR, $ 100,000 HIV RAD: Structural approaches to vaccine development, 2001, NIH, $ 340,000 PI - Transcutaneous Immunization for Tetanus Booster, 2002, NIAID Phase 2 SBIR, $ 851,767 Development of Broad Platform Immunostimulatory Cancer Vaccine, 2002, NIST, $ 3,467,618 Skin Immunization with SIV and HIV Antigen, 2002, NIAID SBIR, $ 399,790 Transcutaneous Immunization for Tetanus Booster, 2003, NIAID Phase 2 SBIR, $ vaccine development, 2001, NIH, $ 340,000 PI - Transcutaneous Immunization for Tetanus Booster, 2002, NIAID Phase 2 SBIR, $ 851,767 Development of Broad Platform Immunostimulatory Cancer Vaccine, 2002, NIST, $ 3,467,618 Skin Immunization with SIV and HIV Antigen, 2002, NIAID SBIR, $ 399,790 Transcutaneous Immunization for Tetanus Booster, 2003, NIAID Phase 2 SBIR, $ Vaccine, 2002, NIST, $ 3,467,618 Skin Immunization with SIV and HIV Antigen, 2002, NIAID SBIR, $ 399,790 Transcutaneous Immunization for Tetanus Booster, 2003, NIAID Phase 2 SBIR, $ 811,042